Dr. Sivapriya Kirubakaran - Cancer Chemical Biology lab
Indian Institute of Technology Gandhinagar
“Here’s to a decade of groundbreaking discoveries, tireless research, and endless possibilities – Celebrating 10 years of excellence in SVL lab!”
Recent Lab News
Check out our recent work on targeting TLK1 kinase for GBM Therapy!
These findings indicate that TLK1 is one of the upregulated kinases in GBM and phenothiazine-based TLK1 inhibitors could be a promising treatment option for GBM patients..
Congratulations Dr. Bhanu, Dimple, and team!
Out Now in ACS Infectious Diseases on H. Pylori work!
The present study reports the development of methylpyrazole-substituted benzimidazoles as small molecule inhibitors of H. pylori IMPDH with a nanomolar range of enzyme inhibition.
Congratulations Haritha!
Our New studies on Temozolomide cocrystals with enhanced dissolution, stability, and biological towards GBM is now published in JMS!
Congratulations Bhanu, Delna, Gurudutt, Divita and team!
A recent review from our lab on exploring the pivotal role of ATR and ATM kinases in DNA damage and their promising inhibitors that are currently undergoing clinical trials. This cutting-edge research sheds light on the intricate mechanisms underlying DNA damage response and opens doors to potential breakthroughs in cancer therapy.
SPK98 – a Torrin2 analog, was employed as an ATR kinase inhibitor.
Congrats Bhanu!
A recent publication from our lab showed phenothiazines’ potency as a TLK inhibitor.
Congratulations, Delna and the team!
Increased solubility with comparable potency of an ATP competitive inhibitor, Gefitinib.
Congo Althaf, Pranav, Dimple, and the team!
New patent granted for J54 molecule
Congratulations to the entire team!
Recent patent granted for RAS inhibitors.
Kudos to the team!
A glimpse of interview by Ms. Spoorty and Dr. Archana
‘Dr. R Gopalan Endowment Prize 2022’ by Madras Christian College, Chennai
Recent Publication on H. pylori IMPDH from our group
Our very recent startup - "PBG Kinomics"
Introducing a new drug candidate to the market is a complex and time-demanding process that at least costs pharmaceuticals an average of billion dollars and 10-15 years of research and development. Out of the four stages of drug discovery, the critical yet time-consuming process is identifying the hit and valid drug candidate for the target of interest. This process covers at least 5-6 years in the overall phase of drug discovery. Hence, reducing this gap would eventually decrease the time gap in identifying the hit molecules and fast-track the drug discovery process. Our previous findings with TTK, a protein kinase that is highly overexpressed in breast cancer, we aim to develop the protein kinase assay to screen our in-house designed small molecule as a TTK inhibitor. The project goals are to i) design and develop the protein expression and purification assay for TTK and ii) develop a protein inhibition assay for screening the small molecules. The project will further be taken up to more proteins to design the assay kit.
Welcome to Sivapriya Kirubakaran’s lab
The Modern Era of Cancer Therapeutics
What do we do as a researcher?
Our laboratory focuses specifically on molecular targets and their exploration in the discovery and development of selective cancer therapeutic agents. We employ strategies for the intelligent combination of therapeutic agents that are selective for a specific molecular target to produce an efficacious response and overcome the mechanisms of drug resistance.
